{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Protagenic Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"PTIX"},"Address":{"label":"Address","value":"149 FIFTH AVENUE,SUITE 500, NEW YORK, New York, 10010, United States"},"Phone":{"label":"Phone","value":"+1 212 994-8200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders."},"CompanyUrl":{"label":"Company Url","value":"https://www.protagenic.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew Slee","title":"Chief Operating Officer"},{"name":"Robert Benjamin Stein","title":"Director & Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}